Xanthine oxidase inhibitors are associated with reduced risk of cardiovascular disease

Abstract As previous studies have reported finding an association between hyperuricemia and the development of cardiovascular and chronic kidney disease, hyperuricemia is thought to be an independent risk factor for hypertension and diabetic mellitus. However, we have not been able to determine whet...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Hirotaka Saito, Kenichi Tanaka, Tsuyoshi Iwasaki, Akira Oda, Shuhei Watanabe, Makoto Kanno, Hiroshi Kimura, Michio Shimabukuro, Koichi Asahi, Tsuyoshi Watanabe, Junichiro James Kazama
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/05a79b92278a486b9d5ae6e777f6cab9
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:05a79b92278a486b9d5ae6e777f6cab9
record_format	dspace
spelling	oai:doaj.org-article:05a79b92278a486b9d5ae6e777f6cab92021-12-02T14:01:20ZXanthine oxidase inhibitors are associated with reduced risk of cardiovascular disease10.1038/s41598-020-80835-82045-2322https://doaj.org/article/05a79b92278a486b9d5ae6e777f6cab92021-01-01T00:00:00Zhttps://doi.org/10.1038/s41598-020-80835-8https://doaj.org/toc/2045-2322Abstract As previous studies have reported finding an association between hyperuricemia and the development of cardiovascular and chronic kidney disease, hyperuricemia is thought to be an independent risk factor for hypertension and diabetic mellitus. However, we have not been able to determine whether the use of xanthine oxidase inhibitors can reduce cardiovascular disease. The present study used the longitudinal data of the Fukushima Cohort Study to investigate the relationship between the use of xanthine oxidase inhibitors and cardiovascular events in patients with cardiovascular risks. During the 3-year period between 2012 and 2014, a total of 2724 subjects were enrolled in the study and followed. A total of 2501 subjects had hypertension, diabetic mellitus, dyslipidemia, or chronic kidney disease, and were identified as having cardiovascular risks. The effects of xanthine oxidase inhibitor use on the development of cardiovascular events was evaluated in these patients using a time to event analysis. During the observational periods (median 2.7 years), the incidence of cardiovascular events was 20.7 in subjects with xanthine oxidase inhibitor and 11.2 (/1000 person-years, respectively) in those without. Although a univariate Cox regression analysis showed that the risk of cardiovascular events was significantly higher in subjects administered xanthine oxidase inhibitors (HR = 1.87, 95% CI 1.19–2.94, p = 0.007), the risk was significantly lower in subjects administered a xanthine oxidase inhibitor after adjustment for covariates (HR = 0.48, 95% CI 0.26–0.91; p = 0.024) compared to those without. Xanthine oxidase inhibitor use was associated with reduced risk of cardiovascular disease in patients with cardiovascular risk factors.Hirotaka SaitoKenichi TanakaTsuyoshi IwasakiAkira OdaShuhei WatanabeMakoto KannoHiroshi KimuraMichio ShimabukuroKoichi AsahiTsuyoshi WatanabeJunichiro James KazamaNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-8 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Hirotaka Saito Kenichi Tanaka Tsuyoshi Iwasaki Akira Oda Shuhei Watanabe Makoto Kanno Hiroshi Kimura Michio Shimabukuro Koichi Asahi Tsuyoshi Watanabe Junichiro James Kazama Xanthine oxidase inhibitors are associated with reduced risk of cardiovascular disease
description	Abstract As previous studies have reported finding an association between hyperuricemia and the development of cardiovascular and chronic kidney disease, hyperuricemia is thought to be an independent risk factor for hypertension and diabetic mellitus. However, we have not been able to determine whether the use of xanthine oxidase inhibitors can reduce cardiovascular disease. The present study used the longitudinal data of the Fukushima Cohort Study to investigate the relationship between the use of xanthine oxidase inhibitors and cardiovascular events in patients with cardiovascular risks. During the 3-year period between 2012 and 2014, a total of 2724 subjects were enrolled in the study and followed. A total of 2501 subjects had hypertension, diabetic mellitus, dyslipidemia, or chronic kidney disease, and were identified as having cardiovascular risks. The effects of xanthine oxidase inhibitor use on the development of cardiovascular events was evaluated in these patients using a time to event analysis. During the observational periods (median 2.7 years), the incidence of cardiovascular events was 20.7 in subjects with xanthine oxidase inhibitor and 11.2 (/1000 person-years, respectively) in those without. Although a univariate Cox regression analysis showed that the risk of cardiovascular events was significantly higher in subjects administered xanthine oxidase inhibitors (HR = 1.87, 95% CI 1.19–2.94, p = 0.007), the risk was significantly lower in subjects administered a xanthine oxidase inhibitor after adjustment for covariates (HR = 0.48, 95% CI 0.26–0.91; p = 0.024) compared to those without. Xanthine oxidase inhibitor use was associated with reduced risk of cardiovascular disease in patients with cardiovascular risk factors.
format	article
author	Hirotaka Saito Kenichi Tanaka Tsuyoshi Iwasaki Akira Oda Shuhei Watanabe Makoto Kanno Hiroshi Kimura Michio Shimabukuro Koichi Asahi Tsuyoshi Watanabe Junichiro James Kazama
author_facet	Hirotaka Saito Kenichi Tanaka Tsuyoshi Iwasaki Akira Oda Shuhei Watanabe Makoto Kanno Hiroshi Kimura Michio Shimabukuro Koichi Asahi Tsuyoshi Watanabe Junichiro James Kazama
author_sort	Hirotaka Saito
title	Xanthine oxidase inhibitors are associated with reduced risk of cardiovascular disease
title_short	Xanthine oxidase inhibitors are associated with reduced risk of cardiovascular disease
title_full	Xanthine oxidase inhibitors are associated with reduced risk of cardiovascular disease
title_fullStr	Xanthine oxidase inhibitors are associated with reduced risk of cardiovascular disease
title_full_unstemmed	Xanthine oxidase inhibitors are associated with reduced risk of cardiovascular disease
title_sort	xanthine oxidase inhibitors are associated with reduced risk of cardiovascular disease
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/05a79b92278a486b9d5ae6e777f6cab9
work_keys_str_mv	AT hirotakasaito xanthineoxidaseinhibitorsareassociatedwithreducedriskofcardiovasculardisease AT kenichitanaka xanthineoxidaseinhibitorsareassociatedwithreducedriskofcardiovasculardisease AT tsuyoshiiwasaki xanthineoxidaseinhibitorsareassociatedwithreducedriskofcardiovasculardisease AT akiraoda xanthineoxidaseinhibitorsareassociatedwithreducedriskofcardiovasculardisease AT shuheiwatanabe xanthineoxidaseinhibitorsareassociatedwithreducedriskofcardiovasculardisease AT makotokanno xanthineoxidaseinhibitorsareassociatedwithreducedriskofcardiovasculardisease AT hiroshikimura xanthineoxidaseinhibitorsareassociatedwithreducedriskofcardiovasculardisease AT michioshimabukuro xanthineoxidaseinhibitorsareassociatedwithreducedriskofcardiovasculardisease AT koichiasahi xanthineoxidaseinhibitorsareassociatedwithreducedriskofcardiovasculardisease AT tsuyoshiwatanabe xanthineoxidaseinhibitorsareassociatedwithreducedriskofcardiovasculardisease AT junichirojameskazama xanthineoxidaseinhibitorsareassociatedwithreducedriskofcardiovasculardisease
_version_	1718392180830109696

Xanthine oxidase inhibitors are associated with reduced risk of cardiovascular disease

Ejemplares similares